Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 09:00:07 03/07/2024 pm IST			5-day change	1st Jan Change
38.55 ^CHF	-0.52%		-3.38%	+9.21%

20/06	Basilea Pharmaceutica to Sell Brain Cancer Drug Candidate to US-based Nonprofit	MT
20/06	Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation	DJ

Basilea Pharmaceutica AG Provides Revenue Guidance for the Year 2020

January 11, 2021 at 11:45 am IST

Basilea Pharmaceutica AG provided revenue guidance for the year 2020. Total revenue is expected to amount to approx. CHF 128 million. Basilea had guided for total revenue of CHF 128-138 million with total revenue contributions from Cresemba and Zevtera of CHF 110-120 million .

Latest news about Basilea Pharmaceutica AG

Basilea Pharmaceutica to Sell Brain Cancer Drug Candidate to US-based Nonprofit	20/06	MT
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation	20/06	DJ
Basilea Pharmaceutica Receives Milestone Payment from Pfizer for Cresemba Sales	16/05	MT
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	16/05	DJ
Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024	03/05	CI
Basilea Pharmaceutica Receives Grant for Antibiotics Program	09/04	MT
Stocks Close in Green as Swiss Inflation Unexpectedly Slows	04/04	MT
European stocks rise ahead of inflation data; Basilea shines	04/04	RE
Basilea announces US FDA approval of antibiotic ZEVTERA(R) (ceftobiprole medocaril) for three indications	04/04	DJ
US FDA Greenlights Basilea Pharmaceutical's Treatment for Bloodstream Infections	04/04	MT
US FDA approves Basilea Pharmaceutica's antibiotic	04/04	RE
US FDA approves Basilea Pharmaceutica's antibiotic	04/04	RE
Basilea Pharmaceutica to Receive Milestone Payment from Pfizer for Antifungal Drug	11/03	MT
Continued strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	11/03	DJ
Stronger-than-Expected US Inflation Rate Weighs on Swiss Equities	13/02	MT
Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2024	13/02	CI
Transcript : Basilea Pharmaceutica AG, 2023 Earnings Call, Feb 13, 2024	13/02
Basilea Pharmaceutica AG Reports Earnings Results for the Full Year Ended December 31, 2023	13/02	CI
Basilea Pharmaceutica Posts Lower FY23 Net Profit; Revenue Up	13/02	MT
Spexis Completes CHF2 Million Sale of Antibiotics Program to Basilea	08/02	MT
Basilea Pharmaceutica to Receive First Milestone Payment for Cresemba from Latin America	19/01	MT
Basilea Pharmaceutica to Buy Preclinical Antibiotics Program Targeting Gram-negative Bacteria from Spexis	15/01	MT
Global markets live: Walt Disney, Qiagen, Mobileye, Apple, CVS Health...	05/01
Basilea Pharmaceutica Eyes Commercialization Partner for Ceftobiprole Ahead of US FDA Verdict	05/01	MT
Global markets live: Fedex, Curevac, Shell, Fedex, Alphabet...	20/12

Chart Basilea Pharmaceutica AG

Duration

Period

More charts

Company Profile

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Basilea Pharmaceutica AG

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

38.75 CHF

Average target price

71.2 CHF

Spread / Average Target

+83.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BASILEA PHARMACEUTICA AG	+9.21%	518M
MODERNA, INC.	+16.59%	44.87B
IQVIA HOLDINGS INC.	-10.62%	37.8B
LONZA GROUP AG	+40.49%	37.61B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.32B
CELLTRION, INC.	-9.78%	27.4B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.32B
UNITED THERAPEUTICS CORPORATION	+41.53%	14.07B
MEDPACE HOLDINGS, INC.	+31.49%	12.5B
BIO-TECHNE CORPORATION	-7.40%	11.23B

Other Biotechnology & Medical Research